1.02
전일 마감가:
$0.8101
열려 있는:
$0.84
하루 거래량:
1.81M
Relative Volume:
1.78
시가총액:
$164.99M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.4024
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
+42.40%
1개월 성능:
+51.61%
6개월 성능:
-90.09%
1년 성능:
-89.73%
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NMRA
Neumora Therapeutics Inc
|
1.02 | 116.25M | 0 | -274.18M | -198.33M | -2.5346 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-10-01 | 개시 | H.C. Wainwright | Buy |
2024-07-22 | 개시 | Needham | Buy |
2024-07-08 | 개시 | Mizuho | Outperform |
2023-12-12 | 개시 | Deutsche Bank | Hold |
2023-10-10 | 개시 | BofA Securities | Buy |
2023-10-10 | 개시 | Guggenheim | Buy |
2023-10-10 | 개시 | JP Morgan | Overweight |
2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
2023-10-10 | 개시 | Stifel | Buy |
2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Ameriprise Financial Inc. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks
BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.
26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World
Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Price T Rowe Associates Inc. MD Cuts Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World
Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia
The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India
Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com
What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World
William Blair Analysts Increase Earnings Estimates for NMRA - Defense World
Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - The Malaysian Reserve
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating - TipRanks
Neumora Therapeutics Venture Debt Facility - Leerink Partners
Neumora Therapeutics (NMRA) Retains Buy Rating with Stable Price Target | NMRA Stock News - GuruFocus
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements - TipRanks
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com
Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Neumora Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
자본화:
|
볼륨(24시간):